CommercialCoverageMedium impact
08.01.66e, Cemiplimab-rwlc (Libtayo®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross expanded coverage for Cemiplimab-rwlc (Libtayo) to include four new cancer indications (Anal Carcinoma, Small Bowel Adenocarcinoma, Rectal Cancer, and Colon Cancer) effective 12/29/2025, aligned with NCCN guidelines. The policy removes specific ICD-10 codes from the document; billing teams must now report the most appropriate diagnosis code supporting medical necessity criteria. This is a coverage expansion that adds new billable scenarios for this PD-L1 inhibitor.
Action Required
By 12/29/2025: Billing and clinical teams must (1) Update billing system and prior authorization workflows to recognize four new covered indications for J9119 (Cemiplimab-rwlc): Anal Carcinoma, Small Bowel Adenocarcinoma, Rectal Cancer, and Colon Cancer; (2) Remove any hard-coded ICD-10 codes from billing templates—providers must now select and document the most appropriate ICD-10 diagnosis code that supports medical necessity per policy criteria; (3) Train providers and prior auth staff on new coverage criteria, including specific scenarios for each cancer type (e.g., dMMR/MSI-H status, POLE/POLD1 mutations, ECOG performance status requirements); (4) Update claim submission process to require supporting documentation of eligibility criteria (genetic testing results, performance status, prior treatment history) for these new indications. Oncology practices and medical reviewers must review the detailed criteria for each cancer type. Failure to update workflows may result in claim denials for legitimate new use cases.